In Waning Days of the Current Administration, FDA Announces Red No. 3 Ban

January 16, 2025

Reading Time : 2 min

On January 15, 2025, FDA announced an order revoking the listings providing for the use of the color additive FD&C Red No. 3 in both foods (including dietary supplements) and ingested drugs. The order is in response to a 2022 petition filed by the Center for Science in the Public Interest, among other food safety and health advocates, which asserted that the additive induces cancer in male rats and urged the agency to revoke authorization. 

FD&C Red No. 3 (also referred to as erythrosine) was first listed in 1907 under the provisions of the Food and Drugs Act of 1906 (Food Inspection Decision 76), and later provisionally listed in 1960 as Red No. 3 for food, drug and cosmetic use.1  In 1969, FD&C Red No. 3 was permanently listed for use in food and ingested drugs and codified in §§74.303 and 74.1303. In 1990, the agency declined to extend the provisional listing of the additive for use in cosmetics and externally applied drugs based on evidence of thyroid neoplasia in rat carcinogenicity studies. However, the decision did not revoke the existing 1969 permanent listing for food and ingested drugs.

In the order, FDA states that based on the available data and information, the FD&C Red No. 3-induced thyroid tumors found in rats are “of limited relevance to humans.” However, citing section 721(b)(5)(B) of the Food, Drug and Cosmetic Act (the FD&C Act), often referred to as the Delaney Clause, the agency concluded that the findings of carcinogenicity render the color additive “unsafe” as a matter of law, regardless of the extent to which the experimental condition of the animal studies provides insight into the health effects of human consumption.2

The order further sets forth an effective date of January 15, 2027, for food and January 18, 2028, for ingested drugs. Subject to any forthcoming challenges to the order, the food industry and drug industry will need to move fairly quickly to assess potential formulation changes in advance of the respective effective dates.


1 See 25 Fed. Reg. 9759, (October 12, 1960).

2 See Section 721(b)(5)(B) of the FD&C Act (stating that a color additive shall be deemed unsafe for any use which will or may result in ingestion of all or part of such additive, if the additive is found by the Secretary to induce cancer when ingested by man or animal, or if it is found by the Secretary, after tests which are appropriate for the evaluation of the safety of additives for use in food, to induce cancer in man or animal.)

Share This Insight

Previous Entries

Eye on FDA

November 5, 2025

Last week, FDA released draft guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies.” This draft guidance reflects an evolution in FDA’s approach to determining whether a comparative clinical study with efficacy endpoints (a comparative efficacy study or CES) is necessary to support a demonstration of biosimilarity. Specifically, the agency notes that a comparative analytical assessment (CAA) is generally more sensitive when it comes to detecting differences between products than a CES.

...

Read More

Eye on FDA

October 27, 2025

On October 23, 2025, FDA released its final guidance regarding Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. The guidance is the third guidance in a four-part series of FDA guidance focused on patient-focused drug development (PFDD) that describe how stakeholders, such as patients, caregivers, researchers, medical product developers and others can submit patient experience data and other relevant information that can be used for medical product development and regulatory decision making.

...

Read More

Eye on FDA

October 23, 2025

On October 16, 2025, the Food and Drug Administration (FDA) unveiled the first group of nine voucher recipients under the Commissioner’s National Priority Voucher (CNPV) pilot program, a program announced by the agency earlier this year that provides a path for accelerated drug review for companies supporting national interests as determined by the Commissioner. The identified areas of priority by the agency include meeting large unmet medical needs, bolstering domestic manufacturing and increasing the affordability of medicines for American patients. As previously noted, the new program, which is not defined in statute or regulations, aims to significantly speed up FDA’s standard 10-12 month review timeline to just 1-2 months after filing an application for a drug or biologic. The agency has touted the  benefit of recipients of the vouchers receiving enhanced access with FDA review staff and a “team-based review” model.

...

Read More

Eye on FDA

October 9, 2025

On September 30, 2025, the Food and Drug Administration (FDA) published a Request for Public Comment to obtain feedback from interested parties on current approaches to measuring and evaluating the performance of AI-enabled medical devices. Specifically, FDA is seeking feedback on best practices, methodologies and approaches for measuring and evaluating real-world performance of AI-enabled medical devices from the public.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.